2nd Quarter - Report

NATIONAL VENTURE CAPITAL ASSOCIATION for NATIONAL VENTURE CAPITAL ASSOCIATION

Firm
Client
Income
—
Expenses
$737,841
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Telecommunications TEC

HR 1468 Secure IT Act: Bills to protect critical infrastructure against cyber based espionage, IP theft and terror attacks; Privacy and Information Sharing issues; S.21 Cybersecurity and American Cyber Competitiveness Act of 2013; HR 624 Cyber Intelligence Sharing and Protection Act (CISPA)

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE; Food & Drug Administration (FDA); White House Office

Bills named: S. 21 (113th), H.R. 624 (113th), H.R. 1468 (113th)

Banking BAN

Implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) Implementation of the JOBS Act Review of decimalization study by the SEC, required under the JOBS Act

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: Food & Drug Administration (FDA); Treasury, Dept of; HOUSE OF REPRESENTATIVES; Securities & Exchange Commission (SEC); SENATE; White House Office

Copyright/Patent/Trademark CPT

Shield Act of 2013, HR 845 - provide new limits to Patent Infringement lawsuits brought by non-practicing entities. Monitored issues. Have not taken a position on the legislation. HR 2024- End Anonymous Patents Act, enchanced disclosure of real party interests; S. 866 Patent Reality Improvement Act, expansion of CBM program; S1013: Patent Abuse Reduction Act, disclosure of real party interest.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Treasury, Dept of; Securities & Exchange Commission (SEC)

Bills named: H.R. 845 (113th), S. 866 (113th), H.R. 2024 (113th)

Energy/Nuclear ENG

Cleantech and Energy Policy Issues. New Energy Innovation Tax issues; ARPA-E Funding; HR 2609 FY 2014 Energy and Water Appropriations.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: Treasury, Dept of; White House Office; HOUSE OF REPRESENTATIVES; SENATE; Securities & Exchange Commission (SEC); Food & Drug Administration (FDA)

Bills named: H.R. 2609 (113th)

Immigration IMM

Support for S.310, Startup Act 3.0; S.169 Immigration Innovation Act of 2013; S.189 Startup VISA Act of 2013; Gang of 8 Bipartisan Framework for Comprehensive Immigration Reform; Invest VISA, Entrepreneurial VISA, HR 2131 S744 Border Security, Economic Opportunity and Immigration Modernization Act

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: Food & Drug Administration (FDA); SENATE; Treasury, Dept of; Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; White House Office

Bills named: H.R. 2131 (113th), S. 189 (113th), S. 310 (113th), S. 169 (113th)

Science/Technology SCI

Basic science research funding

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Treasury, Dept of; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); White House Office

Taxation/Internal Revenue Code TAX

Taxation of carried interest: capital gains tax policy; energy tax extenders; Energy Innovation Tax; Ways and Means "partnership" tax reform discussion draft

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: SENATE; White House Office; Food & Drug Administration (FDA); Treasury, Dept of; Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES

Health Issues HCR

No bill #: Lobbied Congress to work the FDA to create a new approval pathway that could help expediate the development of certain drugs that address unmet medical needs, referred to as a special medical use pathway which can be used for a broad set of discussions No bill #: Lobbied Congress on the need for a transparent regulatory pathway for market-based reimbursement for advanced diagnostics. FDA Medical Mobile Apps

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
MARK HEESEN —
KELLY SLONE —

Contacted: Treasury, Dept of; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); White House Office; SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.